US › Healthcare

Liminatus Pharma, Inc. Class A Common Stock (LIMN)

US · Healthcare · Biotechnology

$3.39+1.80%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.4M

EPS

$-0.03

Key statistics

Market cap

$4.7M

Forward P/E

0.0

P/B

15.50

Book value

$0.27

EPS (TTM)

$-24.00

52-week high

$141.50

52-week low

$3.42

50-day MA

$5.35

200-day MA

$17.54

Beta

0.71

Shareholding

Insiders

33.75%

Institutions

1.41%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	1.01%
Cygnus Capital Advisors, LLC	0.52%
Geode Capital Management, LLC	0.18%
Jane Street Group LLC	0.11%
UBS Group AG	0.08%
Vanguard Capital Management, LLC	0.08%
Virtu Financial LLC	0.04%
Vanguard Fiduciary Trust Co	0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Liminatus Pharma, Inc. Class A Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.